GlassScriptPhysician profile
Adam T Cherry
NPI 1770805673
$15,101.69
in general payments reported to CMS, 2019-2025
31 companies · $3,518 in 2025
The $3,518 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,936 · 2022: $3,000 · 2023: $1,189 · 2024: $5,458 · 2025: $3,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,280 · Food and Beverage: $3,797 · Travel and Lodging: $1,338 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,280.40 |
| Food and Beverage | $3,797.09 |
| Travel and Lodging | $1,337.79 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $3,960.36 | 2021-2025 | Orladeyo |
| Biocryst Pharmaceuticals, INC. | $2,765.79 | 2024-2025 | Orladeyo |
| Glaxosmithkline, LLC. | $1,427.23 | 2021-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $1,424.77 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Csl Behring | $834.11 | 2021-2025 | Hizentra, Haegarda |
| Regeneron Healthcare Solutions, INC. | $796.99 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $627.98 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Amgen INC. | $382.49 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $349.23 | 2021-2025 | |
| Kaleo, INC. | $266.14 | 2021-2023 | Auvi-Q |
| Octapharma USA, INC. | $234.69 | 2021-2025 | Octagam Immune Globulin (Human), Panzyga |
| Grifols USA, LLC | $226.90 | 2021-2022 | |
| Blueprint Medicines Corporation | $213.45 | 2023-2025 | Ayvakit |
| Genentech USA, INC. | $196.84 | 2021-2025 | Xolair |
| Pharming Healthcare, INC. | $193.26 | 2023-2025 | Ruconest |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.41 | 2021 | |
| Pfizer INC. | $160.43 | 2021-2025 | |
| Abbvie INC. | $152.99 | 2022 | |
| Alk-Abello, INC | $145.08 | 2021 | |
| Lilly USA, LLC | $132.38 | 2024 | Ebglyss |
| Genzyme Corporation | $106.87 | 2021-2022 | |
| Tersera Therapeutics LLC | $63.72 | 2024 | Quzyttir |
| Phathom Pharmaceuticals, INC. | $61.33 | 2024 | Voquezna |
| Verona Pharma, INC. | $49.94 | 2025 | Ohtuvayre |
| Bio Products Laboratory USA, INC. | $30.88 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $26.25 | 2025 | |
| Organon LLC | $24.41 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $18.20 | 2022 | |
| Mylan Specialty L.P. | $17.00 | 2021 | |
| Adma Biomanufacturing LLC | $12.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.